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The expression of Fas ligand has recently been pro-
posed as a novel tumor escape mechanism for melan-
oma. To establish the characteristics of Fas ligand
expression during the course of melanoma progression
we performed a longitudinal study analyzing primary
tumors as well as subsequently evolving metastases. In
primary melanoma Fas ligand was expressed in two
of 20 lesions; this expression was weak and restricted
to few parts of the tumors. The Fas ligand positive
primary melanomas were rather thick, i.e., 8.5 and
3.8 mm, versus a median of 2.4 mm of the remaining
tumors. In contrast, for metastatic melanoma Fas
ligand expression was present in six of 11 cases investi-
gated. The metastases of primary tumors displaying
Fas ligand maintained its expression. As Fas ligand
The Fas protein (CD95) is a cell surface receptor thatupon cross-linking transduces apoptotic signals insusceptible cells. The corresponding ligand, Fas ligand(FasL), is a type II membrane protein of the tumornecrosis factor family. FasL acts upon direct cell
contact (Nagata, 1994). Soluble FasL counteracts the effects of the
cellular molecule (Suda et al, 1997; Tanaka et al, 1998). Fas is
expressed in a variety of cells of lymphoid and nonlymphoid origin,
as well as in many malignant cell lines; in contrast, FasL expression
in normal tissues is restricted to activated T cells, natural killer
cells, and macrophage lineages (Nagata, 1994; Suda et al, 1995;
Griffith et al, 1996). Principally, the Fas/FasL system is thought to
be involved in the regulation of homeostasis of the immune system
(Lynch et al, 1995; Griffith et al, 1996). Moreover, it is involved
in the maintenance of immune tolerance in the anterior chamber
of the eye, the testis, and placenta, contributing to the immune-
privileged status of these tissues (Griffith et al, 1996; Uckan
et al, 1997).
There is increasing evidence that the Fas/FasL system is involved
in tumor-mediated immune suppression. Implications have been
found in some hematologic malignancies (Tanaka et al, 1996),
gastrointestinal tumors (Strand et al, 1996; Benett et al, 1998), lung
carcinoma (Niehans et al, 1997), primary cerebral tumors (Gratas
et al, 1997), and ovarian carcinoma (Rabinowich et al, 1998).
Furthermore, Hahne et al (1996) reported that the FasL protein is
present in human melanoma, which may promote the evasion of
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positive melanoma cells are capable of inducing
apoptosis in susceptible cells, e.g., Fas positive tumor
infiltrating lymphocytes, we tested for the presence of
apoptotic cells in situ by terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling. This
analysis revealed that apoptotic cells were present
within the Fas ligand positive tumors. The number of
apoptotic cells, however, never exceeded 5% of the
total cells. Thus, Fas ligand mediated apoptosis does
not seem to be a major immune escape mechanism
for melanoma but its expression correlates with the
stage of melanoma. Key words: apoptosis/immune escape
mechanism/tumor progression. J Invest Dermatol 112:899–
902, 1999
antitumor immune responses because in situ assays revealed that
the infiltrating leukocytes underwent apoptosis at a high rate.
As FasL is absent in normal melanocytes, it should be upregulated
during tumorigenesis and melanoma progression (Hahne et al,
1996). Herein we characterize FasL expression both in primary
melanoma as well as in subsequent metastases of these primaries in
a longitudinal study.
MATERIALS AND METHODS
Tumor samples Fresh tumor samples from 20 primary and 11 sub-
sequently evolving metastatic melanomas as well as 17 metastatic tumors
with no available primary lesions were snap frozen in liquid nitrogen
immediately after surgery and stored at –80°C. All metastatic lesions were
cutaneous metastases.
Immunohistology Frozen sections were fixed in cold acetone for
10 min followed by removal of endogenous peroxidase with 0.03% H2O2
and blocking of nonspecific binding with 10% species-specific serum in
1% bovine serum albumin/phosphate-buffered saline. For FasL analysis,
the monoclonal anti-FasL antibody G247-4 (Pharmingen, San Diego, CA)
was used. To identify tumor infiltrating T cells an anti-CD3 antibody
(Dianova, Hamburg, Germany) was used on serial sections. Antibodies
with identical isotypes reacting with irrelevant epitopes served as negative
controls. Antibodies were overlaid on to serial sections at a dilution of
1:500 and slides were incubated in a humid chamber for 30 min. With
phosphate-buffered saline washes between every step, a biotinylated link
antibody was applied for 10 min followed by peroxidase linked to
streptavidin for 10 min. After another wash 3-amino-9-ethylcarbazol and
H2O2 was added (AEC substrate kit, DAKO, Hamburg, Germany) and
the slides were incubated in the dark for 10 min. Counter staining was
performed with hematoxylin.
In situ apoptosis detection Frozen sections of metastases were acetone-
fixed and apoptotic cells were detected using the terminal deoxynucleotidyl
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Table I. Expression of FasL in primary and subsequently evolving metastatic melanoma and detection of apoptotic cells
Age (y) Gender Primary tumors FasL expression Metastases FasL expression CD3 stainingc Apoptotic cellsd
Breslow thickness (mm)
Frequencya Intensityb Frequencya Intensityb
53 male 8.6 Ø Ø 11 1
71 male 8.5 1 1 11 11 11 1
39 female 6.2 Ø
69 male 4.0 Ø 1 1 11 1
69 male 3.8 11 1 111 111 111 1
68 female 3.6 Ø
68 female 3.3 Ø Ø 1 Ø
51 male 3.1 Ø 11 11 11 1
68 male 2.8 Ø
45 male 2.7 Ø Ø 11 Ø
59 female 2.5 Ø 1 11 1 1
75 male 2.3 Ø Ø 1 Ø
44 male 2.2 Ø
48 female 2.2 Ø
57 female 2.1 Ø 11 1 11 1
30 female 2.0 Ø Ø 1 Ø
68 male 2.0 Ø
67 female 1.9 Ø
62 male 1.9 Ø
40 female 1.8 Ø
aØ, no; 1, less than 5%; 11, between 5 and 50%; 111, more than 50% positive cells.
b1, dim; 11, intermediate; 111, bright.
cGrading of CD31 melanoma infiltrating cells (1, absent; 11, non-brisk; 111, brisk; according to Clemente et al, 1996).
dApoptotic cells were detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (Ø, no; 1, less than 5%).
transferase-mediated dUTP nick end labeling assay; cells containing frag-
mented single chain DNA are labeled with digoxigenin-11-dUTP and
subsequently stained by immunoperoxidase. The assay was performed
according to the manufacturer’s directions (Oncor, Heidelberg, Germany).
Negative controls were made by omitting the terminal deoxynucleotidyl
transferase enzyme on representative slides while DNase I treated slides
served as positive controls.
RESULTS
FasL is predominantly expressed on metastatic
melanoma Although expression of FasL has been described for
most metastatic melanoma, detected both in vitro and in situ, it is
not expressed on normal melanocytes. In order to test whether
FasL expression is upregulated during melanoma progression, we
performed a longitudinal study using primary tumors and sub-
sequently evolving metastatic lesions. Patients’ characteristics are
given in Table I. FasL expression was present in two primary
tumors and six metastatic lesions; hence, the percentage of positive
lesions increased from 10 to 55% during melanoma progression
(Table I). The expression of FasL in primary tumors was not
homogeneous but restricted to few parts of the tumors suggesting
a clonal expansion of FasL1 melanoma cells (Fig 1a). The two
primary tumors displaying FasL expression were rather thick, i.e.,
3.8 and 8.5 mm of tumor thickness, versus median of 2.4 mm for
the FasL– melanomas. Furthermore, both FasL1 primaries gave rise
to subsequent metastasis which not only maintained FasL expression
but showed an even more intense staining (Fig 1b). Owing to the
small number of events no statistical analysis was performed. The
remaining metastatic lesions displaying FasL expression developed
from FasL– primaries. Still, although serial sections of primary
tumors were performed we cannot exclude that parts of the tumor
expressing FasL were missed. This notion is particularly important
if the expression pattern of FasL in the positive primary tumors is
taken into account.
To establish the relative frequency of FasL expression on meta-
static melanoma 17 additional cutaneous metastases were character-
ized regarding FasL expression. FasL was present at various degrees
in nine of these 17 tumors; thus, 54% of the lesions were FasL
positive (Table II). The summarized data of the two series indicate
that the FasL are expressed in approximately 50% of melanoma
lesions metastatic to the skin.
FasL expression is associated with the occurrence of apop-
totic cells in situ It has been suggested that FasL expression
might induce apoptosis in Fas-expressing tumor infiltrating lympho-
cytes; thus, FasL expression would contribute to the immune escape
of melanoma. In order to test this hypothesis we analyzed all
metastatic tumors from the first series for the presence of apoptotic
cells using the terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling technique. With this approach apoptotic
cells could be detected in seven of 11 tumors (Table I). Six of
these also displayed FasL expression on the melanoma cells. The
number of apoptotic cells, however, never exceeded 5%. It should
be emphasized that the technique used does not disclose the nature
of these apoptotic cells. Hence, it is not possible to formally prove
whether the apoptotic cells depict tumor infiltrating lymphocytes
or melanoma cells, even if the morphologic appearance of the
apoptotic cells suggest their lymphatic origin (Fig 1c) and serial
sections stained with an anti-CD3 antibody demonstrated that the
apoptotic cells were localized in the same areas where CD31 cells
accumulated (Fig 1d).
DISCUSSION
Recently, Fas/FasL interactions have been accounted for the
immune-privileged state of the eye, testis, and placenta. Further-
more, the expression of FasL on different tumors including melan-
oma have been reported, suggesting a novel immune escape
mechanism. As FasL is absent on normal melanocytes, it is supposed
to be upregulated during tumorigenesis or melanoma progression
(Hahne et al, 1996). Thus, the present study was designed to
determine FasL expression in primary melanoma and subsequently
evolving metastases. In primary tumors FasL expression was only
present in about 10%, while in metastatic lesions FasL was present
in more than 50%. The latter was confirmed by the detection of
FasL in a second series of experiments which comprises solely
metastatic tumors. It should be stressed that only skin metastases
were analyzed. Thus, the expression of FasL seems to be linked to
the stage of disease with predominant expression in metastatic
lesions. In order to analyse the functional relevance of FasL
expression we tested for the presence of apoptotic cells within
metastatic tumors. This analysis revealed a significant, but low (less
than 5%) number of such cells. The origin of these cells remains
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Figure 1. Detection of FasL expression
and apoptosis in melanoma. Immuno-
histology staining with an anti-FasL
monoclonal antibody of a primary melanoma
(a) and of a subsequently evolving metastasis
(b); representative sections are shown. In situ
detection of apoptotic cells in a metastasis
detected by terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling
as described under Materials and Methods
(c). Exemplary cells that were assessed as
apoptotic are indicated by arrowheads. A
subsequent section of this lesion was
subjected to immunostaining with an anti-
CD3 antibody (d). Sections were counter-
stained with hematoxylin. Scale bar: 30 µm.
Table II. Expression of FasL in metastatic lesions
(nonlongitudinal analysis)
Age (y) Gender FasL expression
Frequencya Intensityb
80 male Ø
76 female Ø
75 male Ø
73 male 111 111
73 female 1 11
70 male 1 1
66 male 1 111
66 male Ø
64 female 1 1
64 female Ø
62 female 1 11
61 female Ø
60 male 11 1
53 male 1 11
45 male 111 111
41 female Ø
21 female Ø
aØ, no; 1, less than 5%; 11, between 5 and 50%; 111, more than 50%
positive cells.
b1, dim; 11, intermediate; 111, bright.
elusive, but morphologic features and their localization in areas of
CD3 expression are highly suggestive for them being tumor
infiltrating lymphocytes.
In a recent report Benett et al (1998) describe a variable
extent of FasL expression in primary esophageal carcinomas which
correlated significantly to the occurrence of apoptotic cells
expressing CD45. Human melanoma cells express FasL and induce
apoptosis in infiltrating T cells (Hahne et al, 1996). Our present
results do confirm these findings. Neither their nor our data,
however, exclude that other Fas-expressing cells, i.e., granulocytes,
natural killer cells, or melanoma cells themselves contribute to the
observed pool of apoptotic cells within the tumor (Liles et al,
1996). Thus, both early nonspecific immune responses as well as
specific T cell mediated could be inhibited by Fas/FasL interactions.
Interestingly, it was shown that the expression of cellular FLIPL
(FLICE-inhibitory protein, long form) by Fas1 melanoma cells
render these cells nonsusceptible to FasL-induced signals; hence,
prohibiting autocrine or paracrine suicide (Irmler et al, 1997).
It should be noted that T cells need to be susceptible for the
FasL-mediated apoptosis. The susceptibility of T cells is dependent
on the stage of cell activation, with resting and early activated, i.e.,
1–3 d after stimulation, T cells being resistant to Fas-induced
apoptosis, whereas the majority of days 4–6-activated T cells
undergo apoptosis after cross-linking of Fas (Alderson et al, 1995).
Rivoltini et al (1998) demonstrated that melanoma-reactive CD41
and CD81 T cell clones were not influenced by FasL expression
of their corresponding melanoma targets as well as soluble FasL or
FasL1 lymphocytes. The fact that these antigen-specific T cells are
resistant to FasL-induced apoptosis suggests that the proposed
immune escape mechanism is not an universal phenomenon. Our
data and that of previous studies, however, indicate that apoptosis
occurs in melanoma-infiltrating lymphocytes even if it is not
prominent or restricted to only susceptible cells.
FasL expression of melanoma cell lines has been correlated with
tumorigenicity in an experimental model. Transfer of FasL1 B16-
F10 melanoma cells into syngeneic wild-type as well as FasL-
deficient gld mice led to increased tumorigenicity while the injection
of cells into lpr, i.e., Fas-negative, mice led to reduced tumor
growth (Hahne et al, 1996). In our study we observed an increased
expression of FasL in cutaneous metastases as compared with their
progenitor primaries and FasL expression being restricted to thick
tumors; thus, FasL expression is likely to correlate with tumorigenic-
ity of melanoma cells. A recent nonlongitudinal study demonstrating
the expression of FasL on advanced primary melanoma and lymph
node metastases but not benign melanocytic lesions corroborates
with this hypothesis (Maeda et al, 1998).
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